These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20689264)

  • 1. List of drugs in development for neurodegenerative diseases: update June 2010.
    Pogačić Kramp V; Herrling P
    Neurodegener Dis; 2011; 8(1-2):44-94. PubMed ID: 20689264
    [No Abstract]   [Full Text] [Related]  

  • 2. List of drugs in development for neurodegenerative diseases: update June 2009.
    Pogacić Kramp V; Herrling P
    Neurodegener Dis; 2009; 6(4):165-212. PubMed ID: 19696517
    [No Abstract]   [Full Text] [Related]  

  • 3. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 4. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO; Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract]   [Full Text] [Related]  

  • 5. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 6. List of drugs in development for neurodegenerative diseases. Update June 2008.
    Pogacić V; Herrling P
    Neurodegener Dis; 2009; 6(1-2):37-86. PubMed ID: 18679022
    [No Abstract]   [Full Text] [Related]  

  • 7. List of drugs in development for neurodegenerative diseases: update October 2011.
    Pogačić Kramp V
    Neurodegener Dis; 2012; 9(4):210-83. PubMed ID: 22222285
    [No Abstract]   [Full Text] [Related]  

  • 8. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 9. List of drugs in development for neurodegenerative diseases. Update March 2005.
    Valentine L; Kwon MO; Herrling P
    Neurodegener Dis; 2004; 1(6):269-322. PubMed ID: 16908978
    [No Abstract]   [Full Text] [Related]  

  • 10. Endocannabinoids and psychopathology: the therapy inside.
    Drago F
    Pharmacol Res; 2007 Nov; 56(5):357-9. PubMed ID: 17942319
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies.
    Cummings JL; Zhong K
    Nat Rev Drug Discov; 2006 Jan; 5(1):64-74. PubMed ID: 16485346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. List of drugs in development for neurodegenerative diseases.
    Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(1):50-70. PubMed ID: 16908974
    [No Abstract]   [Full Text] [Related]  

  • 13. 'Emancipated' biotechs offer new drugs for neurodegeneration.
    Basu P
    Nat Med; 2003 Aug; 9(8):981. PubMed ID: 12894143
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug development. Biotech thinking comes to academic medical centers.
    Alper J
    Science; 2003 Feb; 299(5611):1303-5. PubMed ID: 12610271
    [No Abstract]   [Full Text] [Related]  

  • 15. [The importance of public-private cooperation. Comment on Vandereycken].
    Koerselman GF
    Tijdschr Psychiatr; 2006; 48(2):131-3. PubMed ID: 16958196
    [No Abstract]   [Full Text] [Related]  

  • 16. [Not Available].
    Fischer A
    Drug Res (Stuttg); 2017 Nov; 67(S 01):S9. PubMed ID: 29069674
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry].
    Vandereycken W
    Tijdschr Psychiatr; 2006; 48(2):119-29. PubMed ID: 16958195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatric drugs and children.
    Jellinek MS
    Science; 2003 May; 300(5621):901. PubMed ID: 12738837
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract]   [Full Text] [Related]  

  • 20. [Reaction to 'Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry' and to 'The importance of public-private cooperation. Comment on Vandereycken'].
    Buis WM
    Tijdschr Psychiatr; 2006; 48(6):500-1; author reply 501-3. PubMed ID: 16956013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.